Full Press Release Details
Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease.
IMMP
Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease
Key Takeaway: Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)